Please assess the completion status of the following clinical trial:

Trial Title: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 75 years of age with an HLA-identical sibling donor~* One of the following disease categories:~  * Acute myelogenous leukemia - high risk CR1 (as evidenced by preceding MDS, intermediate to high risk cytogenetics, ≥ 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia; CR2+. All patients must be in CR as defined by hematological recovery (ANC \> 0.5x 109/L), AND \<5% blasts by light microscopy within the bone marrow with a cellularity of ≥15%.~ * Acute lymphocytic leukemia - high risk CR1 \[t(9;22), t (1:19), t(4;11) or other MLL rearrangements\] or \>1cycle to obtain CR; CR2+. All patients must be in CR as defined by hematological recovery (ANC \> 0.5x 109/L), AND \<5% blasts by light microscopy within the bone marrow with a cellularity of ≥15%.~ * Chronic myelogenous leukemia all types except blast crisis (note treated blast crisis in chronic phase is eligible)~ * Non-Hodgkin lymphoma or Hodgkin lymphoma demonstrating chemosensitive disease~ * Myelodysplastic syndrome with severe pancytopenia, leading to either transfusion dependency or increased risk for infections~* Performance status: Karnofsky ≥ 60%~* Adequate organ function within 28 days of study enrollment defined as:~  * Liver: SGOT and SGPT \< 5.0 x ULN; total bilirubin \< 3 x ULN~ * Renal: serum creatinine \< 2.0 mg/dl or glomerular filtration rate (GFR) \> 40 mL/min/1.73m2. Patients with a creatinine \> 1.2 mg/dl or a history of renal dysfunction must have glomerular filtration rate (GFR) \> 40 mL/min/1.73m2~ * Albumin: \> 2.5 g/dL~ * Cardiac: No decompensated CHF or uncontrolled arrhythmia; ejection fraction \> 35% within 6 weeks prior to study enrollment~ * Pulmonary: No O2 requirements; DLCO \> 30% predicted within 6 weeks prior to study enrollment~* If recent mold infection (e.g. aspergillus) must have minimum of 30 days of therapy and responsive disease and be cleared by Infectious Disease~* Sexually active females of child bearing potential and males must agree to use effective contraception for the duration of the transplant period~* Voluntary written consent~Exclusion Criteria:~* Pregnancy or breast feeding - women of childbearing potential must have a negative pregnancy test within 28 days of study enrollment.~* Prior myeloablative transplant within previous 3 months of study enrollment.~* Evidence of HIV infection or known HIV positive serology.~* Active serious infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Administered 3 x 10\^6 iTregs/kg infusion
- Cohort 2 (Type: EXPERIMENTAL): Administered 3 x 10\^7 iTregs/kg infusion
- Cohort 3 (Type: EXPERIMENTAL): Administered 3 x 10\^8 iTregs/kg infusion
- Cohort 4 (Type: EXPERIMENTAL): Administered 10 x 10\^8 iTregs/kg infusion
- Cohort 5 Extension (Type: EXPERIMENTAL): Administered 10 x 10\^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.

Based on this trial design, predict the completion outcome and termination type (if applicable).